Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Cohen

Showing results (1111-1120 of 1,179) with videos related to

Pageof 118
Sort By:
The Lancet. Haematology|August 30, 2016
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE studyMarjolein P A Brekelmans, Walter Ageno, Ludo F Beenen, et al.
European Journal of Internal Medicine|August 23, 2020
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countriesAlexander T Cohen, Ulrich Hoffmann, Philippe Hainaut, et al.
The Lancet. Haematology|April 1, 2016
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trialsMartin H Prins, Anthonie W A Lensing, Tim A Brighton, et al.
Circulation|February 21, 2023
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa InhibitorsTruman J Milling, Saskia Middeldorp, Lizhen Xu, et al.
Lancet (London, England)|February 26, 2008
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial, M G Bousser, J Bouthier, et al.
Thrombosis and Haemostasis|April 14, 2017
The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE RegistryAlexander T Cohen, Anselm K Gitt, Rupert Bauersachs, et al.
Thrombosis Research|September 20, 2020
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 monthsGiancarlo Agnelli, Ulrich Hoffmann, Philippe Hainaut, et al.
Thrombosis and Haemostasis|August 19, 2016
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studiesMarcello Di Nisio, Maria C Vedovati, Antoni Riera-Mestre, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical ExtentMarjolein P A Brekelmans, Harry R Büller, Michele F Mercuri, et al.
European Heart Journal|January 17, 2023
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk scoreMaria A de Winter, Harry R Büller, Marc Carrier, et al.
Pageof 118

Showing results (1111-1120 of 1,179) with videos related to

Sort By:
Pageof 118
The Lancet. Haematology|August 30, 2016
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE studyMarjolein P A Brekelmans, Walter Ageno, Ludo F Beenen, et al.
European Journal of Internal Medicine|August 23, 2020
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countriesAlexander T Cohen, Ulrich Hoffmann, Philippe Hainaut, et al.
The Lancet. Haematology|April 1, 2016
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trialsMartin H Prins, Anthonie W A Lensing, Tim A Brighton, et al.
Circulation|February 21, 2023
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa InhibitorsTruman J Milling, Saskia Middeldorp, Lizhen Xu, et al.
Lancet (London, England)|February 26, 2008
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial, M G Bousser, J Bouthier, et al.
Thrombosis and Haemostasis|April 14, 2017
The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE RegistryAlexander T Cohen, Anselm K Gitt, Rupert Bauersachs, et al.
Thrombosis Research|September 20, 2020
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 monthsGiancarlo Agnelli, Ulrich Hoffmann, Philippe Hainaut, et al.
Thrombosis and Haemostasis|August 19, 2016
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studiesMarcello Di Nisio, Maria C Vedovati, Antoni Riera-Mestre, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical ExtentMarjolein P A Brekelmans, Harry R Büller, Michele F Mercuri, et al.
European Heart Journal|January 17, 2023
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk scoreMaria A de Winter, Harry R Büller, Marc Carrier, et al.
Pageof 118